https://scholars.lib.ntu.edu.tw/handle/123456789/473318
標題: | Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast | 作者: | HUANG-CHUN LIEN Chen Y.-L. Juang Y.-L. YUNG-MING JENG |
公開日期: | 2015 | 出版社: | Springer New York LLC | 卷: | 150 | 期: | 2 | 起(迄)頁: | 447-455 | 來源出版物: | Breast Cancer Research and Treatment | 摘要: | Mutations in HER2 gene have been identified in a small subset of breast cancer cases. Identification of HER2 mutation has therapeutic implications for breast cancer, but whether a subgroup of breast cancer with a higher frequency of HER2 mutation exists, remains unknown. We analyzed HER2 mutation and pathologic factors on 73 formalin-fixed, paraffin-embedded samples, including 21 pleomorphic invasive lobular carcinoma (p-ILC) cases, 3 pleomorphic lobular carcinoma in situ (p-LCIS) cases, and 49 classic invasive lobular carcinoma (c-ILC) cases. Mutations were identified through direct sequencing. HER2 overexpression and amplification were determined through immunohistochemistry and fluorescent in situ hybridization. Six mutations were identified, including five in the 24 p-ILC or p-LCIS (p-ILC/p-LCIS) cases (20.8?%) and one in the 49 c-ILC cases (2.0?%), and the difference in frequency was significant (p?=?0.013). Eight of the 24 (33.3?%) p-ILC/p-LCIS cases exhibited HER2 amplification or overexpression (amplification/overexpression), which was significantly higher than in the c-ILC cases (1/49, 2?%). Mutation and amplification/overexpression were mutually exclusive. HER2 mutations were identified more frequently in the p-ILC/p-LCIS cases with extensive apocrine change (p?=?0.018). Combined HER2 alterations through mutation or amplification/overexpression were more frequently identified in p-ILC/p-LCIS cases without estrogen receptor expression. The high frequency (54.1?%, 13/24) of combined HER2 alterations in the p-ILC/p-LCIS cases suggests a crucial role of HER2 in the pathogenesis of p-ILC/p-LCIS. Because of the reported responsiveness of HER2 mutation to anti-HER2 therapy, p-ILC patients without HER2 amplification/overexpression should receive HER2 mutation analysis to identify this therapeutically relevant target. ? 2015, Springer Science+Business Media New York. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925448716&doi=10.1007%2fs10549-015-3336-0&partnerID=40&md5=0d2ce2733b1313161a52044008bcda95 https://scholars.lib.ntu.edu.tw/handle/123456789/473318 |
ISSN: | 0167-6806 | DOI: | 10.1007/s10549-015-3336-0 | SDG/關鍵字: | epidermal growth factor receptor 2; ERBB2 protein, human; breast tumor; female; gene amplification; gene expression; gene frequency; genetics; human; lung carcinoma; metabolism; mutation; nucleotide sequence; pathology; Base Sequence; Breast Neoplasms; Carcinoma, Lobular; DNA Mutational Analysis; Female; Gene Amplification; Gene Expression; Gene Frequency; Humans; Mutation; Receptor, ErbB-2 |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。